{"bekendtgoerelseNoegle":{"noticeId":{"value":"2ea07466-95f9-4486-904b-0b62a147be59"},"noticeVersion":{"value":"01"},"noticePublicationNumber":{"value":"00373008-2025"}},"htmlDA":"\n\n \n 1 Køber1.1 KøberOfficielt navn: Amgros I/S\n Køberens retlige status: Offentligretligt organ\n Den ordregivende myndigheds aktivitet: Sundhed\n \n 1.1 KøberOfficielt navn: Landspítali Háskólasjúkrahús\n Køberens retlige status: Offentligretligt organ\n Den ordregivende myndigheds aktivitet: Sundhed\n \n 1.1 KøberOfficielt navn: Sykehusinnkjøp HF, divisjon legemidler\n Køberens retlige status: Offentligretligt organ\n Den ordregivende myndigheds aktivitet: Sundhed\n \n \n 2 Procedure2.1 ProcedureTitel: Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a\n Beskrivelse: Denmark, Norway and Iceland have entered into cooperation regarding the procurement\n of pharmaceuticals. The countries will jointly procure and award framework agreements\n in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain\n pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group,\n the pharmaceuticals are tendered under each lot no. for the purpose of supplying the\n Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as\n 1 market) see the tender specification. The obligation to deliver the pharmaceuticals\n in Iceland is subject to the precondition that the supplier obtains an exemption regarding\n printed labels and leaflets. If the supplier does not obtain such exemption the agreement\n will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and\n Appendix 6.\n Identifikator for proceduren: 96e9d894-f9c6-4087-a328-696fdd71d6eb\n Tidligere bekendtgørelse: 134266-2024\n Udbudsprocedure: Offentligt udbud\n 2.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n \n 2.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n 2.1.3 VærdiAnslået værdi eksklusiv moms: 18.146.993 Euro\n Rammeaftalens maksimumværdi: 18.750.000 Euro\n \n 2.1.4 Generelle oplysningerYderligere oplysninger: The procurement procedure is subject to Danish law and any complaints of the procurement\n procedure shall be lodged with the Danish Complaints Board for Public Procurement\n (Klagenævnet for udbud), see section 5.1.12. The Contracting Authorities have considered\n whether the tender group could be further subdivided. The Contracting Authorities\n have deemed that this is not the case based on the considerations of economies of\n scale, which will not be realizable with a further subdivision as well as costs and\n patient safety considerations related to the subsequent management of contract- and\n pharmaceuticals. In relation to sections 2.1.3 and 5.1.5 it should be noted that the\n estimated value indicated in section 2.1.3 is the total estimated value of all lot\n numbers for the duration of the framework agreement, including the option of renewal,\n see section 5.1.4. Section 5.1.5 sets out the estimated value for each lot number,\n including the option of renewal, see section 5.1.4. The value is based on the AIP\n (\"Apotekernes Indkøbspris\" published by the Danish Medicines Agency) of the pharmaceuticals.\n It should furthermore be noted that the estimated value is based on historic consumption\n data and that the actual purchase under a framework agreement may deviate significantly\n from the estimate, see section 5.1, paragraph 5.6 of the tender specifications and\n clause 4.2 of the framework agreement.
When submitting a tender, suppliers must\n use the European Single Procurement Document (ESPD) in the tendering system for the\n declaration regarding the compulsory grounds for exclusion set out in sections 135-136\n of the Danish Public Procurement Act (udbudsloven) (the Act can be found at www.retsinformation.dk).\n Further information on the completion and application of the ESPD in the tender process\n is available in the guide drawn up by Amgros in this respect and in the \"Instructions\n for the European Single Procurement Document\" drawn up by the Danish Competition and\n Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s)\n to whom the Contracting Authorities intend to award the framework agreement must also,\n before the award, provide documentation to the Contracting Authorities regarding the\n absence of compulsory groundsfor exclusion as set out in sections 152-153 of the Public\n Procurement Act. The Contracting Authorities are not entitled to exclude a supplier\n who is subject to one or more of the mandatory exclusion grounds set out insections\n 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation\n that the supplier is reliable, even if the supplier is subject to one or more of the\n grounds for exclusion set out in section138 of the Public Procurement Act. The Contracting\n Authorities reserve the right to carry out a so-called \"self-cleaning\" process if\n relevant.
The supplier is required to confirm that they do not fall under the\n exclusion criteria outlined in section 134a of the Danish Public Procurement Act.\n However, they are not required to provide documentation to support this confirmation.\n It is noted that this tender falls under Article 5k of Regulation (EU) No. 833/2014,\n as amended by Regulation (EU) 2022/1269, which prohibits the awarding of contracts\n to Russian companies and Russian-controlled entities. The contracting authority reserves\n the right, at any stage of the tender process, to demand documentation proving that\n economic operators are not subject to this ban. This may include documentation regarding\n the location of establishment and ownership of the entities involved, as well as any\n of their subcontractors.\n \n \n \n \n \n 5 Delkontrakt5.1 Teknisk ID for delkontrakten: LOT-0001\n Beskrivelse: ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection\n Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 2 ml,
Unit: 16 mg,
Quantity\n in units: Denmark: 234.183, Iceland: 9.750.
ATC Code: A04AA01,
Generic Name:\n Ondansetron,
Pharmaceutical form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack\n size: 4 ml,
Unit: 16 mg,
Quantity in units: Denmark: 15.640, Iceland: 10.000.\n
Each lot number is a separate lot for the pharmaceutical indicated and is put\n up for tender independently of the other lot numbers. This means that a tenderer may\n submit a tender for one, several or all lot numbers, and that framework agreements\n will be awarded separately for each lot number. However, the aim is to conclude framework\n agreements with different suppliers for the lot numbers 1 and 2, which are linked\n lot numbers.
If there is only one compliant tender for either lot numbers 1 or\n 2, the framework agreement for the lot number in question is awarded to the supplier\n concerned. The supplier concerned will then be excluded from award on the other of\n the two lot numbers, and the framework agreement will be awarded to the supplier of\n the remaining suppliers offering the “best price-quality ratio”.
If there are\n several compliant tenders for both lot numbers 1 and 2, the award under lot number\n 1 will take precedence. This means that if the same supplier has submitted a tender\n offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are\n several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities\n will only award the supplier concerned a framework agreement for lot number 1, since\n the framework agreement for lot number 2 is awarded to the supplier with the “second\n best price-quality ratio” under the lot number concerned.
If there is only one\n compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded\n to the suppliers of the respective compliant tenders, notwithstanding that this may\n mean that the same supplier will be awarded a framework agreement for both lot numbers\n 1 and 2.
Under the title \"Quantity in units\", an estimated consumption of the\n pharmaceuticals is indicated for each of the countries. It should be noted that this\n estimate corresponds to the historical consumption of the pharmaceuticals put up for\n tender and that suppliers must expect that the actual purchase under a framework agreement\n may deviate significantly from the estimate. Reference is made to paragraph 5.6 of\n the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 1.954.865 Euro\n Rammeaftalens maksimumværdi: 2.000.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0002\n Beskrivelse: ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection\n Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 2 ml,
Unit: 16 mg,
Quantity\n in units: Norway: 165.000.
ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical\n form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 4 ml,
Unit:\n 16 mg,
Quantity in units: Norway 20.000.
Each lot number is a separate lot\n for the pharmaceutical indicated and is put up for tender independently of the other\n lot numbers. This means that a tenderer may submit a tender for one, several or all\n lot numbers, and that framework agreements will be awarded separately for each lot\n number. However, the aim is to conclude framework agreements with different suppliers\n for the lot numbers 1 and 2, which are linked lot numbers.
If there is only one\n compliant tender for either lot numbers 1 or 2, the framework agreement for the lot\n number in question is awarded to the supplier concerned. The supplier concerned will\n then be excluded from award on the other of the two lot numbers, and the framework\n agreement will be awarded to the supplier of the remaining suppliers offering the\n “best price-quality ratio”.
If there are several compliant tenders for both lot\n numbers 1 and 2, the award under lot number 1 will take precedence. This means that\n if the same supplier has submitted a tender offering the “best price-quality ratio”\n for both lot numbers 1 and 2, and there are several compliant tenders for both lot\n numbers 1 and 2, the Contracting Authorities will only award the supplier concerned\n a framework agreement for lot number 1, since the framework agreement for lot number\n 2 is awarded to the supplier with the “second best price-quality ratio” under the\n lot number concerned.
If there is only one compliant tender for both lot numbers\n 1 and 2, the framework agreements will be awarded to the suppliers of the respective\n compliant tenders, notwithstanding that this may mean that the same supplier will\n be awarded a framework agreement for both lot numbers 1 and 2.
Under the title\n \"Quantity in units\", an estimated consumption of the pharmaceuticals is indicated\n for each of the countries. It should be noted that this estimate corresponds to the\n historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 1.335.120 Euro\n Rammeaftalens maksimumværdi: 1.400.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0003\n Beskrivelse: ATC Code: H02AB09,
Generic Name: Hydrocortisone,
Pharmaceutical form: Injection\n Fluid,
Strength: 100 mg,
Unit: 30 mg,
Quantity in units: Norway: 433.333.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 3 and 4, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 3 or 4, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 3 and 4, the award under lot number 3 will take precedence. This\n means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 3 and 4, and there are several compliant tenders for both\n lot numbers 3 and 4, the Contracting Authorities will only award the supplier concerned\n a framework agreement for lot number 3, since the framework agreement for lot number\n 4 is awarded to the supplier with the “second best price-quality ratio” under the\n lot number concerned.
If there is only one compliant tender for both lot numbers\n 3 and 4, the framework agreements will be awarded to the suppliers of the respective\n compliant tenders, notwithstanding that this may mean that the same supplier will\n be awarded a framework agreement for both lot numbers 3 and 4.
Under the title\n \"Quantity in units\", an estimated consumption of the pharmaceuticals is indicated\n for each of the countries. It should be noted that this estimate corresponds to the\n historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 1.294.191 Euro\n Rammeaftalens maksimumværdi: 1.300.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0004\n Beskrivelse: ATC Code: H02AB09,
Generic Name: Hydrocortisone,
Pharmaceutical form: Injection\n Fluid,
Strength: 100 mg,
Unit: 30 mg,
Quantity in units: Denmark: 313.146,\n Iceland: 73.333.
Each lot number is a separate lot for the pharmaceutical indicated\n and is put up for tender independently of the other lot numbers. This means that a\n tenderer may submit a tender for one, several or all lot numbers, and that framework\n agreements will be awarded separately for each lot number. However, the aim is to\n conclude framework agreements with different suppliers for the lot numbers 3 and 4,\n which are linked lot numbers.
If there is only one compliant tender for either\n lot numbers 3 or 4, the framework agreement for the lot number in question is awarded\n to the supplier concerned. The supplier concerned will then be excluded from award\n on the other of the two lot numbers, and the framework agreement will be awarded to\n the supplier of the remaining suppliers offering the “best price-quality ratio”.
If\n there are several compliant tenders for both lot numbers 3 and 4, the award under\n lot number 3 will take precedence. This means that if the same supplier has submitted\n a tender offering the “best price-quality ratio” for both lot numbers 3 and 4, and\n there are several compliant tenders for both lot numbers 3 and 4, the Contracting\n Authorities will only award the supplier concerned a framework agreement for lot number\n 3, since the framework agreement for lot number 4 is awarded to the supplier with\n the “second best price-quality ratio” under the lot number concerned.
If there\n is only one compliant tender for both lot numbers 3 and 4, the framework agreements\n will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 3 and 4.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 1.154.257 Euro\n Rammeaftalens maksimumværdi: 1.200.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0005\n Beskrivelse: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 50 ml,
Unit: 200 mg,
Quantity\n in units: Denmark: 2.760, Iceland: 350.
ATC Code: J02AC01,
Generic Name: Fluconazole,\n
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 100\n ml,
Unit: 200 mg,
Quantity in units: Denmark: 56.360, Iceland: 4.200.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 5 and 6, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 5 or 6, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 5 and 6, the award under lot number 5 will take precedence. This\n means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 5 and 6, and there are several compliant tenders for both\n lot numbers 5 and 6, the Contracting Authorities will only award the supplier concerned\n a framework agreement for lot number 5, since the framework agreement for lot number\n 6 is awarded to the supplier with the “second best price-quality ratio” under the\n lot number concerned.
If there is only one compliant tender for both lot numbers\n 5 and 6, the framework agreements will be awarded to the suppliers of the respective\n compliant tenders, notwithstanding that this may mean that the same supplier will\n be awarded a framework agreement for both lot numbers 5 and 6.
Under the title\n \"Quantity in units\", an estimated consumption of the pharmaceuticals is indicated\n for each of the countries. It should be noted that this estimate corresponds to the\n historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 474.616 Euro\n Rammeaftalens maksimumværdi: 500.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0006\n Beskrivelse: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 50 ml,
Unit: 200 mg,
Quantity\n in units: Norway: 2.500.
ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical\n form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 100 ml,
Unit: 200\n mg,
Quantity in units: Norway: 25.000.
Each lot number is a separate lot for\n the pharmaceutical indicated and is put up for tender independently of the other lot\n numbers. This means that a tenderer may submit a tender for one, several or all lot\n numbers, and that framework agreements will be awarded separately for each lot number.\n However, the aim is to conclude framework agreements with different suppliers for\n the lot numbers 5 and 6, which are linked lot numbers.
If there is only one compliant\n tender for either lot numbers 5 or 6, the framework agreement for the lot number in\n question is awarded to the supplier concerned. The supplier concerned will then be\n excluded from award on the other of the two lot numbers, and the framework agreement\n will be awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 5 and 6,\n the award under lot number 5 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 5 and 6, and there are several compliant tenders for both lot numbers 5 and 6, the\n Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 5, since the framework agreement for lot number 6 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 5 and 6, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 5 and 6.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 203.753 Euro\n Rammeaftalens maksimumværdi: 250.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0007\n Beskrivelse: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 200 ml,
Unit: 200 mg,
Quantity\n in units: Denmark: 48.400, Iceland: 999.
Each lot number is a separate lot for\n the pharmaceutical indicated and is put up for tender independently of the other lot\n numbers. This means that a tenderer may submit a tender for one, several or all lot\n numbers, and that framework agreements will be awarded separately for each lot number.\n However, the aim is to conclude framework agreements with different suppliers for\n the lot numbers 7 and 8, which are linked lot numbers.
If there is only one compliant\n tender for either lot numbers 7 or 8, the framework agreement for the lot number in\n question is awarded to the supplier concerned. The supplier concerned will then be\n excluded from award on the other of the two lot numbers, and the framework agreement\n will be awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 7 and 8,\n the award under lot number 7 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the\n Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 7, since the framework agreement for lot number 8 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 7 and 8, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 7 and 8.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 262.112 Euro\n Rammeaftalens maksimumværdi: 300.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0008\n Beskrivelse: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 200 ml,
Unit: 200 mg,
Quantity\n in units: Norway: 9.999.
Each lot number is a separate lot for the pharmaceutical\n indicated and is put up for tender independently of the other lot numbers. This means\n that a tenderer may submit a tender for one, several or all lot numbers, and that\n framework agreements will be awarded separately for each lot number. However, the\n aim is to conclude framework agreements with different suppliers for the lot numbers\n 7 and 8, which are linked lot numbers.
If there is only one compliant tender\n for either lot numbers 7 or 8, the framework agreement for the lot number in question\n is awarded to the supplier concerned. The supplier concerned will then be excluded\n from award on the other of the two lot numbers, and the framework agreement will be\n awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 7 and 8,\n the award under lot number 7 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the\n Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 7, since the framework agreement for lot number 8 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 7 and 8, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 7 and 8.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 54.150 Euro\n Rammeaftalens maksimumværdi: 100.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0009\n Beskrivelse: ATC Code: J05AB01,
Generic Name: Aciclovir,
Pharmaceutical form: Infusion\n Fluid,
Strength: 25 mg/ml,
Unit: 4 g,
Quantity in units: Norway: 8.750.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 9 and 10, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 9 or 10, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 9 and 10, the award under lot number 9 will take precedence.\n This means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 9 and 10, and there are several compliant tenders for\n both lot numbers 9 and 10, the Contracting Authorities will only award the supplier\n concerned a framework agreement for lot number 9, since the framework agreement for\n lot number 10 is awarded to the supplier with the “second best price-quality ratio”\n under the lot number concerned.
If there is only one compliant tender for both\n lot numbers 9 and 10, the framework agreements will be awarded to the suppliers of\n the respective compliant tenders, notwithstanding that this may mean that the same\n supplier will be awarded a framework agreement for both lot numbers 9 and 10.
Under\n the title \"Quantity in units\", an estimated consumption of the pharmaceuticals is\n indicated for each of the countries. It should be noted that this estimate corresponds\n to the historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 2.205.797 Euro\n Rammeaftalens maksimumværdi: 2.300.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0010\n Beskrivelse: ATC Code: J05AB01,
Generic Name: Aciclovir,
Pharmaceutical form: Infusion\n Fluid,
Strength: 25 mg/ml,
Unit: 4 g,
Quantity in units: Denmark: 8.662,\n Iceland: 44.
Each lot number is a separate lot for the pharmaceutical indicated\n and is put up for tender independently of the other lot numbers. This means that a\n tenderer may submit a tender for one, several or all lot numbers, and that framework\n agreements will be awarded separately for each lot number. However, the aim is to\n conclude framework agreements with different suppliers for the lot numbers 9 and 10,\n which are linked lot numbers.
If there is only one compliant tender for either\n lot numbers 9 or 10, the framework agreement for the lot number in question is awarded\n to the supplier concerned. The supplier concerned will then be excluded from award\n on the other of the two lot numbers, and the framework agreement will be awarded to\n the supplier of the remaining suppliers offering the “best price-quality ratio”.
If\n there are several compliant tenders for both lot numbers 9 and 10, the award under\n lot number 9 will take precedence. This means that if the same supplier has submitted\n a tender offering the “best price-quality ratio” for both lot numbers 9 and 10, and\n there are several compliant tenders for both lot numbers 9 and 10, the Contracting\n Authorities will only award the supplier concerned a framework agreement for lot number\n 9, since the framework agreement for lot number 10 is awarded to the supplier with\n the “second best price-quality ratio” under the lot number concerned.
If there\n is only one compliant tender for both lot numbers 9 and 10, the framework agreements\n will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 9 and 10.
Under the title \"Quantity in units\", an estimated\n consumption of the pharmaceuticals is indicated for each of the countries. It should\n be noted that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 2.194.642 Euro\n Rammeaftalens maksimumværdi: 2.200.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0011\n Beskrivelse: ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion\n Fluid,
Strength: 100 mg/ml,
Pack size: 10 ml,
Unit: 11,429 mg,
Quantity\n in units: Norway: 349.987.
ATC Code: L01BA01,
Generic Name: Methotrexate,\n
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack size:\n 50 ml,
Unit: 11,429 mg,
Quantity in units: Norway: 1.312.451.
Each lot\n number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 11 and 12, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 11 or 12, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 11 and 12, the award under lot number 11 will take precedence.\n This means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 11 and 12, and there are several compliant tenders for\n both lot numbers 11 and 12, the Contracting Authorities will only award the supplier\n concerned a framework agreement for lot number 11, since the framework agreement for\n lot number 12 is awarded to the supplier with the “second best price-quality ratio”\n under the lot number concerned.
If there is only one compliant tender for both\n lot numbers 11 and 12, the framework agreements will be awarded to the suppliers of\n the respective compliant tenders, notwithstanding that this may mean that the same\n supplier will be awarded a framework agreement for both lot numbers 11 and 12.
Under\n the title \"Quantity in units\", an estimated consumption of the pharmaceuticals is\n indicated for each of the countries. It should be noted that this estimate corresponds\n to the historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 849.633 Euro\n Rammeaftalens maksimumværdi: 900.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0012\n Beskrivelse: ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion\n Fluid,
Strength: 100 mg/ml,
Pack size: 10 ml,
Unit: 11,429 mg,
Quantity\n in units: Denmark: 116.721, Iceland: 17.499.
ATC Code: L01BA01,
Generic Name:\n Methotrexate,
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack\n size: 50 ml,
Unit: 11,429 mg,
Quantity in units: Denmark: 1.388.574, Iceland:\n 61.248.
Each lot number is a separate lot for the pharmaceutical indicated and\n is put up for tender independently of the other lot numbers. This means that a tenderer\n may submit a tender for one, several or all lot numbers, and that framework agreements\n will be awarded separately for each lot number. However, the aim is to conclude framework\n agreements with different suppliers for the lot numbers 11 and 12, which are linked\n lot numbers.
If there is only one compliant tender for either lot numbers 11\n or 12, the framework agreement for the lot number in question is awarded to the supplier\n concerned. The supplier concerned will then be excluded from award on the other of\n the two lot numbers, and the framework agreement will be awarded to the supplier of\n the remaining suppliers offering the “best price-quality ratio”.
If there are\n several compliant tenders for both lot numbers 11 and 12, the award under lot number\n 11 will take precedence. This means that if the same supplier has submitted a tender\n offering the “best price-quality ratio” for both lot numbers 11 and 12, and there\n are several compliant tenders for both lot numbers 11 and 12, the Contracting Authorities\n will only award the supplier concerned a framework agreement for lot number 11, since\n the framework agreement for lot number 12 is awarded to the supplier with the “second\n best price-quality ratio” under the lot number concerned.
If there is only one\n compliant tender for both lot numbers 11 and 12, the framework agreements will be\n awarded to the suppliers of the respective compliant tenders, notwithstanding that\n this may mean that the same supplier will be awarded a framework agreement for both\n lot numbers 11 and 12.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 787.664 Euro\n Rammeaftalens maksimumværdi: 800.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0013\n Beskrivelse: ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion\n Fluid,
Strength: 10 mg/ml,
Pack size: 10-50 ml,
Unit: 3 g,
Quantity\n in units: Norway: 10.000.
ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical\n form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 100 ml,
Unit: 3 g,
Quantity\n in units: Norway: 466.667.
Each lot number is a separate lot for the pharmaceutical\n indicated and is put up for tender independently of the other lot numbers. This means\n that a tenderer may submit a tender for one, several or all lot numbers, and that\n framework agreements will be awarded separately for each lot number. However, the\n aim is to conclude framework agreements with different suppliers for the lot numbers\n 13 and 14, which are linked lot numbers.
If there is only one compliant tender\n for either lot numbers 13 or 14, the framework agreement for the lot number in question\n is awarded to the supplier concerned. The supplier concerned will then be excluded\n from award on the other of the two lot numbers, and the framework agreement will be\n awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 13 and 14,\n the award under lot number 13 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 13 and 14, and there are several compliant tenders for both lot numbers 13 and 14,\n the Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 13, since the framework agreement for lot number 14 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 13 and 14, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 13 and 14.
Under the title \"Quantity in units\", an estimated\n consumption of the pharmaceuticals is indicated for each of the countries. It should\n be noted that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 3.069.705 Euro\n Rammeaftalens maksimumværdi: 3.100.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n 5.1 Teknisk ID for delkontrakten: LOT-0014\n Beskrivelse: ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion\n Fluid,
Strength: 10 mg/ml,
Pack size: 10-50 ml,
Unit: 3 g,
Quantity\n in units: Denmark: 3.525, Iceland: 417.
ATC Code: N02BE01,
Generic Name: Paracetamol,\n
Pharmaceutical form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 100\n ml,
Unit: 3 g,
Quantity in units: Denmark: 323.184, Iceland: 33.333.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 13 and 14, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 13 or 14, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 13 and 14, the award under lot number 13 will take precedence.\n This means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 13 and 14, and there are several compliant tenders for\n both lot numbers 13 and 14, the Contracting Authorities will only award the supplier\n concerned a framework agreement for lot number 13, since the framework agreement for\n lot number 14 is awarded to the supplier with the “second best price-quality ratio”\n under the lot number concerned.
If there is only one compliant tender for both\n lot numbers 13 and 14, the framework agreements will be awarded to the suppliers of\n the respective compliant tenders, notwithstanding that this may mean that the same\n supplier will be awarded a framework agreement for both lot numbers 13 and 14.
Under\n the title \"Quantity in units\", an estimated consumption of the pharmaceuticals is\n indicated for each of the countries. It should be noted that this estimate corresponds\n to the historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n \n 5.1.1 FormålKontraktens hovedformål: Varer\n Primær klassifikation (cpv): 33600000 Lægemidler\n Valgmuligheder:Beskrivelse af optioner: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 UdførelsesstedLandsdel (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Anslået varighed\n Varigheds slutdato: 31-03-2029\n \n 5.1.4 FornyelseHøjeste antal fornyelser: 2\n Yderligere oplysninger om fornyelser: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 VærdiAnslået værdi eksklusiv moms: 2.306.484 Euro\n Rammeaftalens maksimumværdi: 2.400.000 Euro\n \n 5.1.6 Generelle oplysningerIndkøbsprojekt, der ikke finansieres med EU-midler\n Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja\n \n 5.1.10 TildelingskriterierKriterium:\n Beskrivelse: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Beskrivelse af den metode, der skal anvendes, hvis vægtningen ikke kan udtrykkes ved hjælp af kriterier: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TeknikkerRammeaftale:Rammeaftale uden fornyet iværksættelse af konkurrence\n \n Oplysninger om det dynamiske indkøbssystem:Intet dynamisk indkøbssystem\n \n \n 5.1.16 Yderligere oplysninger, mægling og gennemgangOrganisation med ansvar for klager: Klagenævnet for Udbud\n Oplysninger om klagefrister: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation, der leverer supplerende oplysninger om udbudsproceduren: Amgros I/S\n Organisation, der sikrer adgang til udbudsdokumenterne offline: Amgros I/S\n Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6 ResultaterRammeaftalernes maksimumværdi i denne bekendtgørelse: 18.750.000 Euro\n 6.1 Resultat delkontrakt-ID: LOT-0001Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 2.000.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Fresenius Kabi\n \n Tilbud – Identifikator: Bidding no. 40605\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0001\n Værdien af tilbuddet: 438.120 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 1 - Fresenius Kabi - Bidding No. 40605\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.3 Ikke-vindende tilbudsgivere:Tilbudsgiver:Officielt navn: Accord Healthcare A/S\n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0002Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 1.400.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Hameln Pharma ApS\n \n Tilbud – Identifikator: Bidding no. 40631\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0002\n Værdien af tilbuddet: 816.960 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 2 - Hameln Pharma ApS - Bidding No. 40631\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.3 Ikke-vindende tilbudsgivere:Tilbudsgiver:Officielt navn: Fresenius Kabi\n \n Tilbudsgiver:Officielt navn: Accord Healthcare A/S\n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 3\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 3\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 3\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0003Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 1.300.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Pfizer ApS\n \n Tilbud – Identifikator: Bidding no. 40625\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0003\n Værdien af tilbuddet: 932.000 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 3 - Pfizer ApS - Bidding No. 40625\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0004Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 1.200.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Pfizer ApS\n \n Tilbud – Identifikator: Bidding no. 40626\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0004\n Værdien af tilbuddet: 820.799 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 4 - Pfizer ApS - Bidding No. 40626\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0005Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 500.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Fresenius Kabi\n \n Tilbud – Identifikator: Bidding no. 40607\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0005\n Værdien af tilbuddet: 79.008 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 5 - Fresenius Kabi - Bidding No. 40607\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.3 Ikke-vindende tilbudsgivere:Tilbudsgiver:Officielt navn: B. Braun Medical A/S\n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0006Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 250.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: B. Braun Medical AS\n \n Tilbud – Identifikator: Bidding no. 40618\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0006\n Værdien af tilbuddet: 324.000 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 6 - B. Braun Medical AS - Bidding No. 40618\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0007Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 300.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Fresenius Kabi\n \n Tilbud – Identifikator: Bidding no. 40608\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0007\n Værdien af tilbuddet: 81.782 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 7 - Fresenius Kabi - Bidding No. 40608\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.3 Ikke-vindende tilbudsgivere:Tilbudsgiver:Officielt navn: B. Braun Medical A/S\n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0008Der er ikke udvalgt en vinder, og konkurrencen er afsluttet.\n Årsagen til at der ikke udvælges en vinder: Der er ikke modtaget nogen tilbud, ansøgninger om deltagelse eller projekter\n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0009Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 2.300.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Accord Healthcare A/S\n \n Tilbud – Identifikator: Bidding no. 40611\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0009\n Værdien af tilbuddet: 1.517.400 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 9 - Accord Healthcare AB - Bidding No. 40611\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0010Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 2.200.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Accord Healthcare A/S\n \n Tilbud – Identifikator: Bidding no. 40612\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0010\n Værdien af tilbuddet: 1.936.740 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 10 - Accord Healthcare AB - Bidding No. 40612\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0011Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 900.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Sandoz A/S\n \n Tilbud – Identifikator: Bidding no. 40615\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0011\n Værdien af tilbuddet: 1.128.980 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 11 - Sandoz A/S - Bidding No. 40615\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0012Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 800.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Sandoz A/S\n \n Tilbud – Identifikator: Bidding no. 40616\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0012\n Værdien af tilbuddet: 1.375.722 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 12 - Sandoz A/S- Bidding No. 40616\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0013Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 3.100.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: B. Braun Medical AS\n \n Tilbud – Identifikator: Bidding no. 40619\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0013\n Værdien af tilbuddet: 1.859.000 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 13 - B. Braun Medical A/S - Bidding No. 40619\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.3 Ikke-vindende tilbudsgivere:Tilbudsgiver:Officielt navn: Baxter A/S\n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 2\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n 6.1 Resultat delkontrakt-ID: LOT-0014Der er udvalgt mindst én vinder.\n Rammeaftale:Den maksimale værdi for rammeaftalen: 2.400.000 Euro\n \n 6.1.2 Oplysninger om vinderneVinder:Officielt navn: Baxter A/S\n \n Tilbud – Identifikator: Bidding no. 40604\n ID for delkontrakt eller gruppe af delkontrakter: LOT-0014\n Værdien af tilbuddet: 1.194.690 Euro\n Tilbuddet blev rangordnet: nej\n \n Kontraktoplysninger:Identifikator for kontrakten: Lot number 14 - Baxter A/S - Bidding No. 40604\n Dato for indgåelse af kontrakten: 30-09-2024\n Organisation, der underskriver kontrakten: Amgros I/S\n \n \n \n 6.1.4 Statistiske oplysningerModtagne tilbud og ansøgninger om deltagelse:Type modtagne indgivelser: TilbudAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud, der er indgivet ad elektronisk vejAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra mikrovirksomheder samt små eller mellemstore virksomhederAntal modtagne tilbud og ansøgninger om deltagelse: 1\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i andre EØS-lande end købers landAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n Type modtagne indgivelser: Tilbud fra tilbudsgivere, der er registreret i lande uden for EØSAntal modtagne tilbud og ansøgninger om deltagelse: 0\n \n \n \n \n \n 8 Organisationer8.1 ORG-0001Officielt navn: Amgros I/S\n Registreringsnummer: 14479880\n Postadresse: Dampfærgevej 22 \n \n \n Landsdel (NUTS): Byen København (DK011)\n \n \n \n \n Internetadresse: https://amgros.dk\n Denne organisations roller:Køber\n Indkøbscentral, der tildeler offentlige kontrakter eller indgår rammeaftaler om bygge- og anlægsarbejder, vareindkøb eller tjenesteydelser tiltænkt andre købere\n \n Organisation, der leverer supplerende oplysninger om udbudsproceduren\n Organisation, der sikrer adgang til udbudsdokumenterne offline\n Organisation, der underskriver kontrakten\n \n \n 8.1 ORG-0002Officielt navn: Landspítali Háskólasjúkrahús\n Registreringsnummer: 500300-2130\n Postadresse: Skaftahlíð 24 \n \n \n Landsdel (NUTS): Höfuðborgarsvæði (IS001)\n \n Enhed: Hulda Harðardóttir\n E-mail: huldahar@landspitali.is\n \n Internetadresse: http://www.rikiskaup.is/\n Denne organisations roller:\n \n \n 8.1 ORG-0003Officielt navn: Sykehusinnkjøp HF, divisjon legemidler\n Registreringsnummer: 916879067\n Postadresse: Grev Wedels Plass 7 5. etasje \n \n \n Landsdel (NUTS): Oslo (NO081)\n \n \n E-mail: legemidler@sykehusinnkjop.no\n \n Internetadresse: http://www.sykehusinnkjop.no\n Denne organisations roller:\n \n \n 8.1 ORG-0004Officielt navn: Klagenævnet for Udbud\n Registreringsnummer: 37795526\n Postadresse: Nævnenes Hus Toldboden 2 \n \n \n Landsdel (NUTS): Østjylland (DK042)\n \n E-mail: klfu@naevneneshus.dk\n \n Internetadresse: https://klfu.naevneneshus.dk\n Denne organisations roller:Organisation med ansvar for klager\n \n \n 8.1 ORG-0005Officielt navn: Konkurrence- og Forbrugerstyrelsen\n Registreringsnummer: 10294819\n Postadresse: Carl Jacobsens vej 35 \n \n \n Landsdel (NUTS): Byen København (DK011)\n \n \n \n Internetadresse: http://www.kfst.dk\n Denne organisations roller:Organisation, der leverer yderligere oplysninger om klageprocedurerne\n \n \n 8.1 ORG-0006Officielt navn: B. Braun Medical A/S\n Registreringsnummer: 20343249\n Postadresse: Dirch Passers Alle 27, 3 sal \n \n \n Landsdel (NUTS): Byen København (DK011)\n \n E-mail: kundeservice-dk@bbraun.com\n \n Internetadresse: https://bbraun.dk\n Denne organisations roller:\n \n \n 8.1 ORG-0007Officielt navn: B. Braun Medical AS\n Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed\n Registreringsnummer: 914 113 172\n Postadresse: Mathilde Henriksens vei 1 \n \n \n Landsdel (NUTS): Østfold (NO083)\n \n E-mail: kundeservice.no@bbraun.com\n \n Internetadresse: https://www.bbraun.no\n Denne organisations roller:\n Vinder af disse delkontrakter: LOT-0006, LOT-0013\n \n \n 8.1 ORG-0008Officielt navn: Fresenius Kabi\n Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed\n Registreringsnummer: 21347809\n Postadresse: Islands Brygge 57 \n \n \n Landsdel (NUTS): Byen København (DK011)\n \n E-mail: info-dk@fresenius-kabi.com\n \n Internetadresse: https://www.fresenius-kabi.dk\n Denne organisations roller:\n Vinder af disse delkontrakter: LOT-0001, LOT-0005, LOT-0007\n \n \n 8.1 ORG-0009Officielt navn: Accord Healthcare A/S\n Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed\n Registreringsnummer: 556810-0258\n Postadresse: Frösundaviks Allé 1 \n \n \n Landsdel (NUTS): Stockholms län (SE110)\n \n E-mail: info_sweden@accord-healthcare.com\n \n Internetadresse: https://www.accord-healthcare.com/se/\n Denne organisations roller:\n Vinder af disse delkontrakter: LOT-0009, LOT-0010\n \n \n 8.1 ORG-0010Officielt navn: Hameln Pharma ApS\n Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed\n Registreringsnummer: 39720213\n Postadresse: Naverland 22 \n \n \n Landsdel (NUTS): Københavns omegn (DK012)\n \n E-mail: rp@hameln-pharma.dk\n \n Internetadresse: https://www.hameln-pharma.com\n Denne organisations roller:\n Vinder af disse delkontrakter: LOT-0002\n \n \n 8.1 ORG-0011Officielt navn: Pfizer ApS\n Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed\n Registreringsnummer: 66351912\n Postadresse: Lautrupvang 8 \n \n \n Landsdel (NUTS): Københavns omegn (DK012)\n \n E-mail: Medical.Information@pfizer.com\n \n Internetadresse: https://www.pfizer.dk\n Denne organisations roller:\n Vinder af disse delkontrakter: LOT-0003, LOT-0004\n \n \n 8.1 ORG-0012Officielt navn: Sandoz A/S\n Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed\n Registreringsnummer: 27744532\n Postadresse: Edvard Thomsens Vej 14 \n \n \n Landsdel (NUTS): Byen København (DK011)\n \n E-mail: info.sandoz-dk@sandoz.com\n \n Internetadresse: https://www.sandoz.dk\n Denne organisations roller:\n Vinder af disse delkontrakter: LOT-0011, LOT-0012\n \n \n 8.1 ORG-0013Officielt navn: Baxter A/S\n Den økonomiske operatørs størrelse: Mikrovirksomhed, lille eller mellemstor virksomhed\n Registreringsnummer: 72246012\n Postadresse: Tobaksvejen 23A \n \n \n Landsdel (NUTS): Københavns omegn (DK012)\n \n E-mail: kundeservice_danmark@baxter.com\n \n Internetadresse: http://www.baxter.dk\n Denne organisations roller:\n Vinder af disse delkontrakter: LOT-0014\n \n \n 8.1 ORG-0000Officielt navn: Publications Office of the European Union\n Registreringsnummer: PUBL\n \n \n Landsdel (NUTS): Luxembourg (LU000)\n \n E-mail: ted@publications.europa.eu\n \n Internetadresse: https://op.europa.eu\n Denne organisations roller:\n \n \n \n Oplysninger om bekendtgørelsenBekendtgørelsens ID: 2ea07466-95f9-4486-904b-0b62a147be59 - 01\n \n Bekendtgørelsestype: Bekendtgørelse om indgåede kontrakter eller koncessionstildeling – standardordningen\n Afsendelsesdato for bekendtgørelsen: 10-06-2025 09:29 +00:00\n Bekendtgørelsens officielle sprog: engelsk \n Bekendtgørelsesnummer: 00373008-2025\n \n Offentliggørelsesdato: 11-06-2025\n \n \n","htmlEN":"\n\n \n 1 Buyer1.1 BuyerOfficial name: Amgros I/S\n Legal type of the buyer: Body governed by public law\n Activity of the contracting authority: Health\n \n 1.1 BuyerOfficial name: Landspítali Háskólasjúkrahús\n Legal type of the buyer: Body governed by public law\n Activity of the contracting authority: Health\n \n 1.1 BuyerOfficial name: Sykehusinnkjøp HF, divisjon legemidler\n Legal type of the buyer: Body governed by public law\n Activity of the contracting authority: Health\n \n \n 2 Procedure2.1 ProcedureTitle: Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a\n Description: Denmark, Norway and Iceland have entered into cooperation regarding the procurement\n of pharmaceuticals. The countries will jointly procure and award framework agreements\n in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain\n pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group,\n the pharmaceuticals are tendered under each lot no. for the purpose of supplying the\n Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as\n 1 market) see the tender specification. The obligation to deliver the pharmaceuticals\n in Iceland is subject to the precondition that the supplier obtains an exemption regarding\n printed labels and leaflets. If the supplier does not obtain such exemption the agreement\n will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and\n Appendix 6.\n Procedure identifier: 96e9d894-f9c6-4087-a328-696fdd71d6eb\n Previous notice: 134266-2024\n \n 2.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n \n 2.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n 2.1.3 ValueEstimated value excluding VAT: 18.146.993 Euro\n Maximum value of the framework agreement: 18.750.000 Euro\n \n 2.1.4 General informationAdditional information: The procurement procedure is subject to Danish law and any complaints of the procurement\n procedure shall be lodged with the Danish Complaints Board for Public Procurement\n (Klagenævnet for udbud), see section 5.1.12. The Contracting Authorities have considered\n whether the tender group could be further subdivided. The Contracting Authorities\n have deemed that this is not the case based on the considerations of economies of\n scale, which will not be realizable with a further subdivision as well as costs and\n patient safety considerations related to the subsequent management of contract- and\n pharmaceuticals. In relation to sections 2.1.3 and 5.1.5 it should be noted that the\n estimated value indicated in section 2.1.3 is the total estimated value of all lot\n numbers for the duration of the framework agreement, including the option of renewal,\n see section 5.1.4. Section 5.1.5 sets out the estimated value for each lot number,\n including the option of renewal, see section 5.1.4. The value is based on the AIP\n (\"Apotekernes Indkøbspris\" published by the Danish Medicines Agency) of the pharmaceuticals.\n It should furthermore be noted that the estimated value is based on historic consumption\n data and that the actual purchase under a framework agreement may deviate significantly\n from the estimate, see section 5.1, paragraph 5.6 of the tender specifications and\n clause 4.2 of the framework agreement.
When submitting a tender, suppliers must\n use the European Single Procurement Document (ESPD) in the tendering system for the\n declaration regarding the compulsory grounds for exclusion set out in sections 135-136\n of the Danish Public Procurement Act (udbudsloven) (the Act can be found at www.retsinformation.dk).\n Further information on the completion and application of the ESPD in the tender process\n is available in the guide drawn up by Amgros in this respect and in the \"Instructions\n for the European Single Procurement Document\" drawn up by the Danish Competition and\n Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s)\n to whom the Contracting Authorities intend to award the framework agreement must also,\n before the award, provide documentation to the Contracting Authorities regarding the\n absence of compulsory groundsfor exclusion as set out in sections 152-153 of the Public\n Procurement Act. The Contracting Authorities are not entitled to exclude a supplier\n who is subject to one or more of the mandatory exclusion grounds set out insections\n 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation\n that the supplier is reliable, even if the supplier is subject to one or more of the\n grounds for exclusion set out in section138 of the Public Procurement Act. The Contracting\n Authorities reserve the right to carry out a so-called \"self-cleaning\" process if\n relevant.
The supplier is required to confirm that they do not fall under the\n exclusion criteria outlined in section 134a of the Danish Public Procurement Act.\n However, they are not required to provide documentation to support this confirmation.\n It is noted that this tender falls under Article 5k of Regulation (EU) No. 833/2014,\n as amended by Regulation (EU) 2022/1269, which prohibits the awarding of contracts\n to Russian companies and Russian-controlled entities. The contracting authority reserves\n the right, at any stage of the tender process, to demand documentation proving that\n economic operators are not subject to this ban. This may include documentation regarding\n the location of establishment and ownership of the entities involved, as well as any\n of their subcontractors.\n \n \n \n \n \n 5 Lot5.1 Lot technical ID: LOT-0001\n Description: ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection\n Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 2 ml,
Unit: 16 mg,
Quantity\n in units: Denmark: 234.183, Iceland: 9.750.
ATC Code: A04AA01,
Generic Name:\n Ondansetron,
Pharmaceutical form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack\n size: 4 ml,
Unit: 16 mg,
Quantity in units: Denmark: 15.640, Iceland: 10.000.\n
Each lot number is a separate lot for the pharmaceutical indicated and is put\n up for tender independently of the other lot numbers. This means that a tenderer may\n submit a tender for one, several or all lot numbers, and that framework agreements\n will be awarded separately for each lot number. However, the aim is to conclude framework\n agreements with different suppliers for the lot numbers 1 and 2, which are linked\n lot numbers.
If there is only one compliant tender for either lot numbers 1 or\n 2, the framework agreement for the lot number in question is awarded to the supplier\n concerned. The supplier concerned will then be excluded from award on the other of\n the two lot numbers, and the framework agreement will be awarded to the supplier of\n the remaining suppliers offering the “best price-quality ratio”.
If there are\n several compliant tenders for both lot numbers 1 and 2, the award under lot number\n 1 will take precedence. This means that if the same supplier has submitted a tender\n offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are\n several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities\n will only award the supplier concerned a framework agreement for lot number 1, since\n the framework agreement for lot number 2 is awarded to the supplier with the “second\n best price-quality ratio” under the lot number concerned.
If there is only one\n compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded\n to the suppliers of the respective compliant tenders, notwithstanding that this may\n mean that the same supplier will be awarded a framework agreement for both lot numbers\n 1 and 2.
Under the title \"Quantity in units\", an estimated consumption of the\n pharmaceuticals is indicated for each of the countries. It should be noted that this\n estimate corresponds to the historical consumption of the pharmaceuticals put up for\n tender and that suppliers must expect that the actual purchase under a framework agreement\n may deviate significantly from the estimate. Reference is made to paragraph 5.6 of\n the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 1\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 1.954.865 Euro\n Maximum value of the framework agreement: 2.000.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0002\n Description: ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical form: Injection\n Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 2 ml,
Unit: 16 mg,
Quantity\n in units: Norway: 165.000.
ATC Code: A04AA01,
Generic Name: Ondansetron,
Pharmaceutical\n form: Injection Fluid (ampule),
Strength: 2 mg/ml,
Pack size: 4 ml,
Unit:\n 16 mg,
Quantity in units: Norway 20.000.
Each lot number is a separate lot\n for the pharmaceutical indicated and is put up for tender independently of the other\n lot numbers. This means that a tenderer may submit a tender for one, several or all\n lot numbers, and that framework agreements will be awarded separately for each lot\n number. However, the aim is to conclude framework agreements with different suppliers\n for the lot numbers 1 and 2, which are linked lot numbers.
If there is only one\n compliant tender for either lot numbers 1 or 2, the framework agreement for the lot\n number in question is awarded to the supplier concerned. The supplier concerned will\n then be excluded from award on the other of the two lot numbers, and the framework\n agreement will be awarded to the supplier of the remaining suppliers offering the\n “best price-quality ratio”.
If there are several compliant tenders for both lot\n numbers 1 and 2, the award under lot number 1 will take precedence. This means that\n if the same supplier has submitted a tender offering the “best price-quality ratio”\n for both lot numbers 1 and 2, and there are several compliant tenders for both lot\n numbers 1 and 2, the Contracting Authorities will only award the supplier concerned\n a framework agreement for lot number 1, since the framework agreement for lot number\n 2 is awarded to the supplier with the “second best price-quality ratio” under the\n lot number concerned.
If there is only one compliant tender for both lot numbers\n 1 and 2, the framework agreements will be awarded to the suppliers of the respective\n compliant tenders, notwithstanding that this may mean that the same supplier will\n be awarded a framework agreement for both lot numbers 1 and 2.
Under the title\n \"Quantity in units\", an estimated consumption of the pharmaceuticals is indicated\n for each of the countries. It should be noted that this estimate corresponds to the\n historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 2\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 1.335.120 Euro\n Maximum value of the framework agreement: 1.400.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0003\n Description: ATC Code: H02AB09,
Generic Name: Hydrocortisone,
Pharmaceutical form: Injection\n Fluid,
Strength: 100 mg,
Unit: 30 mg,
Quantity in units: Norway: 433.333.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 3 and 4, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 3 or 4, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 3 and 4, the award under lot number 3 will take precedence. This\n means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 3 and 4, and there are several compliant tenders for both\n lot numbers 3 and 4, the Contracting Authorities will only award the supplier concerned\n a framework agreement for lot number 3, since the framework agreement for lot number\n 4 is awarded to the supplier with the “second best price-quality ratio” under the\n lot number concerned.
If there is only one compliant tender for both lot numbers\n 3 and 4, the framework agreements will be awarded to the suppliers of the respective\n compliant tenders, notwithstanding that this may mean that the same supplier will\n be awarded a framework agreement for both lot numbers 3 and 4.
Under the title\n \"Quantity in units\", an estimated consumption of the pharmaceuticals is indicated\n for each of the countries. It should be noted that this estimate corresponds to the\n historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 3\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 1.294.191 Euro\n Maximum value of the framework agreement: 1.300.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0004\n Description: ATC Code: H02AB09,
Generic Name: Hydrocortisone,
Pharmaceutical form: Injection\n Fluid,
Strength: 100 mg,
Unit: 30 mg,
Quantity in units: Denmark: 313.146,\n Iceland: 73.333.
Each lot number is a separate lot for the pharmaceutical indicated\n and is put up for tender independently of the other lot numbers. This means that a\n tenderer may submit a tender for one, several or all lot numbers, and that framework\n agreements will be awarded separately for each lot number. However, the aim is to\n conclude framework agreements with different suppliers for the lot numbers 3 and 4,\n which are linked lot numbers.
If there is only one compliant tender for either\n lot numbers 3 or 4, the framework agreement for the lot number in question is awarded\n to the supplier concerned. The supplier concerned will then be excluded from award\n on the other of the two lot numbers, and the framework agreement will be awarded to\n the supplier of the remaining suppliers offering the “best price-quality ratio”.
If\n there are several compliant tenders for both lot numbers 3 and 4, the award under\n lot number 3 will take precedence. This means that if the same supplier has submitted\n a tender offering the “best price-quality ratio” for both lot numbers 3 and 4, and\n there are several compliant tenders for both lot numbers 3 and 4, the Contracting\n Authorities will only award the supplier concerned a framework agreement for lot number\n 3, since the framework agreement for lot number 4 is awarded to the supplier with\n the “second best price-quality ratio” under the lot number concerned.
If there\n is only one compliant tender for both lot numbers 3 and 4, the framework agreements\n will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 3 and 4.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 4\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 1.154.257 Euro\n Maximum value of the framework agreement: 1.200.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0005\n Description: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 50 ml,
Unit: 200 mg,
Quantity\n in units: Denmark: 2.760, Iceland: 350.
ATC Code: J02AC01,
Generic Name: Fluconazole,\n
Pharmaceutical form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 100\n ml,
Unit: 200 mg,
Quantity in units: Denmark: 56.360, Iceland: 4.200.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 5 and 6, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 5 or 6, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 5 and 6, the award under lot number 5 will take precedence. This\n means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 5 and 6, and there are several compliant tenders for both\n lot numbers 5 and 6, the Contracting Authorities will only award the supplier concerned\n a framework agreement for lot number 5, since the framework agreement for lot number\n 6 is awarded to the supplier with the “second best price-quality ratio” under the\n lot number concerned.
If there is only one compliant tender for both lot numbers\n 5 and 6, the framework agreements will be awarded to the suppliers of the respective\n compliant tenders, notwithstanding that this may mean that the same supplier will\n be awarded a framework agreement for both lot numbers 5 and 6.
Under the title\n \"Quantity in units\", an estimated consumption of the pharmaceuticals is indicated\n for each of the countries. It should be noted that this estimate corresponds to the\n historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 5\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 474.616 Euro\n Maximum value of the framework agreement: 500.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0006\n Description: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 50 ml,
Unit: 200 mg,
Quantity\n in units: Norway: 2.500.
ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical\n form: Infusion Fluid,
Strength: 2 mg/ml,
Pack size: 100 ml,
Unit: 200\n mg,
Quantity in units: Norway: 25.000.
Each lot number is a separate lot for\n the pharmaceutical indicated and is put up for tender independently of the other lot\n numbers. This means that a tenderer may submit a tender for one, several or all lot\n numbers, and that framework agreements will be awarded separately for each lot number.\n However, the aim is to conclude framework agreements with different suppliers for\n the lot numbers 5 and 6, which are linked lot numbers.
If there is only one compliant\n tender for either lot numbers 5 or 6, the framework agreement for the lot number in\n question is awarded to the supplier concerned. The supplier concerned will then be\n excluded from award on the other of the two lot numbers, and the framework agreement\n will be awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 5 and 6,\n the award under lot number 5 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 5 and 6, and there are several compliant tenders for both lot numbers 5 and 6, the\n Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 5, since the framework agreement for lot number 6 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 5 and 6, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 5 and 6.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 6\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 203.753 Euro\n Maximum value of the framework agreement: 250.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0007\n Description: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 200 ml,
Unit: 200 mg,
Quantity\n in units: Denmark: 48.400, Iceland: 999.
Each lot number is a separate lot for\n the pharmaceutical indicated and is put up for tender independently of the other lot\n numbers. This means that a tenderer may submit a tender for one, several or all lot\n numbers, and that framework agreements will be awarded separately for each lot number.\n However, the aim is to conclude framework agreements with different suppliers for\n the lot numbers 7 and 8, which are linked lot numbers.
If there is only one compliant\n tender for either lot numbers 7 or 8, the framework agreement for the lot number in\n question is awarded to the supplier concerned. The supplier concerned will then be\n excluded from award on the other of the two lot numbers, and the framework agreement\n will be awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 7 and 8,\n the award under lot number 7 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the\n Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 7, since the framework agreement for lot number 8 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 7 and 8, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 7 and 8.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 7\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 262.112 Euro\n Maximum value of the framework agreement: 300.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0008\n Description: ATC Code: J02AC01,
Generic Name: Fluconazole,
Pharmaceutical form: Infusion\n Fluid,
Strength: 2 mg/ml,
Pack size: 200 ml,
Unit: 200 mg,
Quantity\n in units: Norway: 9.999.
Each lot number is a separate lot for the pharmaceutical\n indicated and is put up for tender independently of the other lot numbers. This means\n that a tenderer may submit a tender for one, several or all lot numbers, and that\n framework agreements will be awarded separately for each lot number. However, the\n aim is to conclude framework agreements with different suppliers for the lot numbers\n 7 and 8, which are linked lot numbers.
If there is only one compliant tender\n for either lot numbers 7 or 8, the framework agreement for the lot number in question\n is awarded to the supplier concerned. The supplier concerned will then be excluded\n from award on the other of the two lot numbers, and the framework agreement will be\n awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 7 and 8,\n the award under lot number 7 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 7 and 8, and there are several compliant tenders for both lot numbers 7 and 8, the\n Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 7, since the framework agreement for lot number 8 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 7 and 8, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 7 and 8.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 8\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 54.150 Euro\n Maximum value of the framework agreement: 100.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n \n \n 5.1 Lot technical ID: LOT-0009\n Description: ATC Code: J05AB01,
Generic Name: Aciclovir,
Pharmaceutical form: Infusion\n Fluid,
Strength: 25 mg/ml,
Unit: 4 g,
Quantity in units: Norway: 8.750.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 9 and 10, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 9 or 10, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 9 and 10, the award under lot number 9 will take precedence.\n This means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 9 and 10, and there are several compliant tenders for\n both lot numbers 9 and 10, the Contracting Authorities will only award the supplier\n concerned a framework agreement for lot number 9, since the framework agreement for\n lot number 10 is awarded to the supplier with the “second best price-quality ratio”\n under the lot number concerned.
If there is only one compliant tender for both\n lot numbers 9 and 10, the framework agreements will be awarded to the suppliers of\n the respective compliant tenders, notwithstanding that this may mean that the same\n supplier will be awarded a framework agreement for both lot numbers 9 and 10.
Under\n the title \"Quantity in units\", an estimated consumption of the pharmaceuticals is\n indicated for each of the countries. It should be noted that this estimate corresponds\n to the historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 9\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 2.205.797 Euro\n Maximum value of the framework agreement: 2.300.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0010\n Description: ATC Code: J05AB01,
Generic Name: Aciclovir,
Pharmaceutical form: Infusion\n Fluid,
Strength: 25 mg/ml,
Unit: 4 g,
Quantity in units: Denmark: 8.662,\n Iceland: 44.
Each lot number is a separate lot for the pharmaceutical indicated\n and is put up for tender independently of the other lot numbers. This means that a\n tenderer may submit a tender for one, several or all lot numbers, and that framework\n agreements will be awarded separately for each lot number. However, the aim is to\n conclude framework agreements with different suppliers for the lot numbers 9 and 10,\n which are linked lot numbers.
If there is only one compliant tender for either\n lot numbers 9 or 10, the framework agreement for the lot number in question is awarded\n to the supplier concerned. The supplier concerned will then be excluded from award\n on the other of the two lot numbers, and the framework agreement will be awarded to\n the supplier of the remaining suppliers offering the “best price-quality ratio”.
If\n there are several compliant tenders for both lot numbers 9 and 10, the award under\n lot number 9 will take precedence. This means that if the same supplier has submitted\n a tender offering the “best price-quality ratio” for both lot numbers 9 and 10, and\n there are several compliant tenders for both lot numbers 9 and 10, the Contracting\n Authorities will only award the supplier concerned a framework agreement for lot number\n 9, since the framework agreement for lot number 10 is awarded to the supplier with\n the “second best price-quality ratio” under the lot number concerned.
If there\n is only one compliant tender for both lot numbers 9 and 10, the framework agreements\n will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 9 and 10.
Under the title \"Quantity in units\", an estimated\n consumption of the pharmaceuticals is indicated for each of the countries. It should\n be noted that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 10\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 2.194.642 Euro\n Maximum value of the framework agreement: 2.200.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0011\n Description: ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion\n Fluid,
Strength: 100 mg/ml,
Pack size: 10 ml,
Unit: 11,429 mg,
Quantity\n in units: Norway: 349.987.
ATC Code: L01BA01,
Generic Name: Methotrexate,\n
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack size:\n 50 ml,
Unit: 11,429 mg,
Quantity in units: Norway: 1.312.451.
Each lot\n number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 11 and 12, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 11 or 12, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 11 and 12, the award under lot number 11 will take precedence.\n This means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 11 and 12, and there are several compliant tenders for\n both lot numbers 11 and 12, the Contracting Authorities will only award the supplier\n concerned a framework agreement for lot number 11, since the framework agreement for\n lot number 12 is awarded to the supplier with the “second best price-quality ratio”\n under the lot number concerned.
If there is only one compliant tender for both\n lot numbers 11 and 12, the framework agreements will be awarded to the suppliers of\n the respective compliant tenders, notwithstanding that this may mean that the same\n supplier will be awarded a framework agreement for both lot numbers 11 and 12.
Under\n the title \"Quantity in units\", an estimated consumption of the pharmaceuticals is\n indicated for each of the countries. It should be noted that this estimate corresponds\n to the historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 11\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 849.633 Euro\n Maximum value of the framework agreement: 900.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0012\n Description: ATC Code: L01BA01,
Generic Name: Methotrexate,
Pharmaceutical form: Infusion\n Fluid,
Strength: 100 mg/ml,
Pack size: 10 ml,
Unit: 11,429 mg,
Quantity\n in units: Denmark: 116.721, Iceland: 17.499.
ATC Code: L01BA01,
Generic Name:\n Methotrexate,
Pharmaceutical form: Infusion Fluid,
Strength: 100 mg/ml,
Pack\n size: 50 ml,
Unit: 11,429 mg,
Quantity in units: Denmark: 1.388.574, Iceland:\n 61.248.
Each lot number is a separate lot for the pharmaceutical indicated and\n is put up for tender independently of the other lot numbers. This means that a tenderer\n may submit a tender for one, several or all lot numbers, and that framework agreements\n will be awarded separately for each lot number. However, the aim is to conclude framework\n agreements with different suppliers for the lot numbers 11 and 12, which are linked\n lot numbers.
If there is only one compliant tender for either lot numbers 11\n or 12, the framework agreement for the lot number in question is awarded to the supplier\n concerned. The supplier concerned will then be excluded from award on the other of\n the two lot numbers, and the framework agreement will be awarded to the supplier of\n the remaining suppliers offering the “best price-quality ratio”.
If there are\n several compliant tenders for both lot numbers 11 and 12, the award under lot number\n 11 will take precedence. This means that if the same supplier has submitted a tender\n offering the “best price-quality ratio” for both lot numbers 11 and 12, and there\n are several compliant tenders for both lot numbers 11 and 12, the Contracting Authorities\n will only award the supplier concerned a framework agreement for lot number 11, since\n the framework agreement for lot number 12 is awarded to the supplier with the “second\n best price-quality ratio” under the lot number concerned.
If there is only one\n compliant tender for both lot numbers 11 and 12, the framework agreements will be\n awarded to the suppliers of the respective compliant tenders, notwithstanding that\n this may mean that the same supplier will be awarded a framework agreement for both\n lot numbers 11 and 12.
Under the title \"Quantity in units\", an estimated consumption\n of the pharmaceuticals is indicated for each of the countries. It should be noted\n that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 12\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 787.664 Euro\n Maximum value of the framework agreement: 800.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0013\n Description: ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion\n Fluid,
Strength: 10 mg/ml,
Pack size: 10-50 ml,
Unit: 3 g,
Quantity\n in units: Norway: 10.000.
ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical\n form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 100 ml,
Unit: 3 g,
Quantity\n in units: Norway: 466.667.
Each lot number is a separate lot for the pharmaceutical\n indicated and is put up for tender independently of the other lot numbers. This means\n that a tenderer may submit a tender for one, several or all lot numbers, and that\n framework agreements will be awarded separately for each lot number. However, the\n aim is to conclude framework agreements with different suppliers for the lot numbers\n 13 and 14, which are linked lot numbers.
If there is only one compliant tender\n for either lot numbers 13 or 14, the framework agreement for the lot number in question\n is awarded to the supplier concerned. The supplier concerned will then be excluded\n from award on the other of the two lot numbers, and the framework agreement will be\n awarded to the supplier of the remaining suppliers offering the “best price-quality\n ratio”.
If there are several compliant tenders for both lot numbers 13 and 14,\n the award under lot number 13 will take precedence. This means that if the same supplier\n has submitted a tender offering the “best price-quality ratio” for both lot numbers\n 13 and 14, and there are several compliant tenders for both lot numbers 13 and 14,\n the Contracting Authorities will only award the supplier concerned a framework agreement\n for lot number 13, since the framework agreement for lot number 14 is awarded to the\n supplier with the “second best price-quality ratio” under the lot number concerned.\n
If there is only one compliant tender for both lot numbers 13 and 14, the framework\n agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding\n that this may mean that the same supplier will be awarded a framework agreement for\n both lot numbers 13 and 14.
Under the title \"Quantity in units\", an estimated\n consumption of the pharmaceuticals is indicated for each of the countries. It should\n be noted that this estimate corresponds to the historical consumption of the pharmaceuticals\n put up for tender and that suppliers must expect that the actual purchase under a\n framework agreement may deviate significantly from the estimate. Reference is made\n to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 13\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 3.069.705 Euro\n Maximum value of the framework agreement: 3.100.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n 5.1 Lot technical ID: LOT-0014\n Description: ATC Code: N02BE01,
Generic Name: Paracetamol,
Pharmaceutical form: Infusion\n Fluid,
Strength: 10 mg/ml,
Pack size: 10-50 ml,
Unit: 3 g,
Quantity\n in units: Denmark: 3.525, Iceland: 417.
ATC Code: N02BE01,
Generic Name: Paracetamol,\n
Pharmaceutical form: Infusion Fluid,
Strength: 10 mg/ml,
Pack size: 100\n ml,
Unit: 3 g,
Quantity in units: Denmark: 323.184, Iceland: 33.333.
Each\n lot number is a separate lot for the pharmaceutical indicated and is put up for tender\n independently of the other lot numbers. This means that a tenderer may submit a tender\n for one, several or all lot numbers, and that framework agreements will be awarded\n separately for each lot number. However, the aim is to conclude framework agreements\n with different suppliers for the lot numbers 13 and 14, which are linked lot numbers.\n
If there is only one compliant tender for either lot numbers 13 or 14, the framework\n agreement for the lot number in question is awarded to the supplier concerned. The\n supplier concerned will then be excluded from award on the other of the two lot numbers,\n and the framework agreement will be awarded to the supplier of the remaining suppliers\n offering the “best price-quality ratio”.
If there are several compliant tenders\n for both lot numbers 13 and 14, the award under lot number 13 will take precedence.\n This means that if the same supplier has submitted a tender offering the “best price-quality\n ratio” for both lot numbers 13 and 14, and there are several compliant tenders for\n both lot numbers 13 and 14, the Contracting Authorities will only award the supplier\n concerned a framework agreement for lot number 13, since the framework agreement for\n lot number 14 is awarded to the supplier with the “second best price-quality ratio”\n under the lot number concerned.
If there is only one compliant tender for both\n lot numbers 13 and 14, the framework agreements will be awarded to the suppliers of\n the respective compliant tenders, notwithstanding that this may mean that the same\n supplier will be awarded a framework agreement for both lot numbers 13 and 14.
Under\n the title \"Quantity in units\", an estimated consumption of the pharmaceuticals is\n indicated for each of the countries. It should be noted that this estimate corresponds\n to the historical consumption of the pharmaceuticals put up for tender and that suppliers\n must expect that the actual purchase under a framework agreement may deviate significantly\n from the estimate. Reference is made to paragraph 5.6 of the tender specifications\n and clause 4.2 in the framework agreement.\n Internal identifier: Lot No. 14\n 5.1.1 PurposeMain nature of the contract: Supplies\n Main classification (cpv): 33600000 Pharmaceutical products\n Options:Description of the options: Clause 8.2 of the framework agreement provides for an option for delivery in a pre-agreement\n period (i.e. before the purchase period begins) and an option for delivery in a post-agreement\n period (i.e. after the purchase period). The two options may be exercised on the terms\n and conditions stipulated in the framework agreement. The estimated duration in section\n 5.1.3 is including the options for renewals. The framework agreements ordinary duration\n is from 1.4.2025 to 31.3.2027.\n \n \n 5.1.2 Place of performanceCountry subdivision (NUTS): Byen København (DK011)\n \n \n \n 5.1.3 Estimated duration\n Duration end date: 31-03-2029\n \n 5.1.4 Renewal\n Other information about renewals: The Contracting Authorities shall be entitled to extend the framework agreement up\n to two times for each pharmaceutical on unchanged terms and conditions by up to 12\n months. See Framework Agreement section 8.2.\n \n 5.1.5 ValueEstimated value excluding VAT: 2.306.484 Euro\n Maximum value of the framework agreement: 2.400.000 Euro\n \n 5.1.6 General informationProcurement Project not financed with EU Funds.\n The procurement is covered by the Government Procurement Agreement (GPA): yes\n \n 5.1.10 Award criteriaCriterion:\n Description: Price is not the only award criterion and all criteria are stated only in the procurement\n documents.\n \n Description of the method to be used if weighting cannot be expressed by criteria: Number of points for a given sub-criterion * the weighting of the sub-criterion specified\n in paragraph 10.1 of the tender specifications.\n \n 5.1.15 TechniquesFramework agreement:Framework agreement, without reopening of competition\n \n Information about the dynamic purchasing system:No dynamic purchase system\n \n \n 5.1.16 Further information, mediation and reviewReview organisation: Klagenævnet for Udbud\n Information about review deadlines: Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act no.\n 593 of 2 June 2016 as amended) the following deadlines apply to the lodging of complaints:\n Complaints of the tendering procedure must be lodged with the Complaints Board for\n Public Procurement within 6 months after the contracting entity has entered into a\n framework agreement calculated from the day after the day when the contracting entity\n has notified the affected applicants and tenderers, see section 7(2), para.(3) of\n the Act. Not later than at the time of lodging a complaint with the Danish Complaints\n Board for Public Procurement, the complainant must notify the contracting authorities\n in writing that a complaint has been lodged with the Danish Complaints Board for Public\n Procurement and whether the complaint was lodged during the standstill period, see\n section 6(4) of the Act. In cases where the complaint was not lodged within the standstill\n period, the complainant must furthermore indicate whether a suspensory effect of the\n complaint has been requested, see clause 6(4) of the Act.\n Organisation providing additional information about the procurement procedure: Amgros I/S\n Organisation providing offline access to the procurement documents: Amgros I/S\n Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen\n Organisation signing the contract: Amgros I/S\n \n \n \n 6 ResultsMaximum value of the framework agreements in this notice: 18.750.000 Euro\n 6.1 Result lot ldentifier: LOT-0001At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 2.000.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Fresenius Kabi\n \n Tender identifier: Bidding no. 40605\n Identifier of lot or group of lots: LOT-0001\n Value of the tender: 438.120 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 1 - Fresenius Kabi - Bidding No. 40605\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.3 Non-winning tenderers:Tenderer:Official name: Accord Healthcare A/S\n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: TendersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0002At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 1.400.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Hameln Pharma ApS\n \n Tender identifier: Bidding no. 40631\n Identifier of lot or group of lots: LOT-0002\n Value of the tender: 816.960 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 2 - Hameln Pharma ApS - Bidding No. 40631\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.3 Non-winning tenderers:Tenderer:Official name: Fresenius Kabi\n \n Tenderer:Official name: Accord Healthcare A/S\n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 3\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 3\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 3\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0003At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 1.300.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Pfizer ApS\n \n Tender identifier: Bidding no. 40625\n Identifier of lot or group of lots: LOT-0003\n Value of the tender: 932.000 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 3 - Pfizer ApS - Bidding No. 40625\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0004At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 1.200.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Pfizer ApS\n \n Tender identifier: Bidding no. 40626\n Identifier of lot or group of lots: LOT-0004\n Value of the tender: 820.799 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 4 - Pfizer ApS - Bidding No. 40626\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0005At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 500.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Fresenius Kabi\n \n Tender identifier: Bidding no. 40607\n Identifier of lot or group of lots: LOT-0005\n Value of the tender: 79.008 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 5 - Fresenius Kabi - Bidding No. 40607\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.3 Non-winning tenderers:Tenderer:Official name: B. Braun Medical A/S\n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0006At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 250.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: B. Braun Medical AS\n \n Tender identifier: Bidding no. 40618\n Identifier of lot or group of lots: LOT-0006\n Value of the tender: 324.000 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 6 - B. Braun Medical AS - Bidding No. 40618\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0007At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 300.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Fresenius Kabi\n \n Tender identifier: Bidding no. 40608\n Identifier of lot or group of lots: LOT-0007\n Value of the tender: 81.782 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 7 - Fresenius Kabi - Bidding No. 40608\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.3 Non-winning tenderers:Tenderer:Official name: B. Braun Medical A/S\n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0008No winner was chosen and the competition is closed.\n The reason why a winner was not chosen: No tenders, requests to participate or projects were received\n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0009At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 2.300.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Accord Healthcare A/S\n \n Tender identifier: Bidding no. 40611\n Identifier of lot or group of lots: LOT-0009\n Value of the tender: 1.517.400 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 9 - Accord Healthcare AB - Bidding No. 40611\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0010At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 2.200.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Accord Healthcare A/S\n \n Tender identifier: Bidding no. 40612\n Identifier of lot or group of lots: LOT-0010\n Value of the tender: 1.936.740 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 10 - Accord Healthcare AB - Bidding No. 40612\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0011At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 900.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Sandoz A/S\n \n Tender identifier: Bidding no. 40615\n Identifier of lot or group of lots: LOT-0011\n Value of the tender: 1.128.980 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 11 - Sandoz A/S - Bidding No. 40615\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0012At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 800.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Sandoz A/S\n \n Tender identifier: Bidding no. 40616\n Identifier of lot or group of lots: LOT-0012\n Value of the tender: 1.375.722 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 12 - Sandoz A/S- Bidding No. 40616\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0013At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 3.100.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: B. Braun Medical AS\n \n Tender identifier: Bidding no. 40619\n Identifier of lot or group of lots: LOT-0013\n Value of the tender: 1.859.000 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 13 - B. Braun Medical A/S - Bidding No. 40619\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.3 Non-winning tenderers:Tenderer:Official name: Baxter A/S\n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 2\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n 6.1 Result lot ldentifier: LOT-0014At least one winner was chosen.\n Framework agreement:Maximum value of the framework agreement: 2.400.000 Euro\n \n 6.1.2 Information about winnersWinner:Official name: Baxter A/S\n \n Tender identifier: Bidding no. 40604\n Identifier of lot or group of lots: LOT-0014\n Value of the tender: 1.194.690 Euro\n The tender was ranked: no\n \n Contract information:Identifier of the contract: Lot number 14 - Baxter A/S - Bidding No. 40604\n Date of the conclusion of the contract: 30-09-2024\n Organisation signing the contract: Amgros I/S\n \n \n \n 6.1.4 Statistical informationReceived tenders or requests to participate:Type of received submissions: TendersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders submitted electronicallyNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from micro, small or medium tenderersNumber of tenders or requests to participate received: 1\n \n Type of received submissions: Tenders from tenderers registered in other European Economic Area countries than the country of the buyerNumber of tenders or requests to participate received: 0\n \n Type of received submissions: Tenders from tenders registered in countries outside of the European Economic AreaNumber of tenders or requests to participate received: 0\n \n \n \n \n \n 8 Organisations8.1 ORG-0001Official name: Amgros I/S\n Registration number: 14479880\n Postal address: Dampfærgevej 22 \n \n \n Country subdivision (NUTS): Byen København (DK011)\n \n Contact point: Flemming Sonne\n \n \n Internet address: https://amgros.dk\n Roles of this organisation:Buyer\n Central purchasing body awarding public contracts or concluding framework agreements for works, supplies or services intended for other buyers\n \n Organisation providing additional information about the procurement procedure\n Organisation providing offline access to the procurement documents\n Organisation signing the contract\n \n \n 8.1 ORG-0002Official name: Landspítali Háskólasjúkrahús\n Registration number: 500300-2130\n Postal address: Skaftahlíð 24 \n \n \n Country subdivision (NUTS): Höfuðborgarsvæði (IS001)\n \n Contact point: Hulda Harðardóttir\n Email: huldahar@landspitali.is\n \n Internet address: http://www.rikiskaup.is/\n Roles of this organisation:\n \n \n 8.1 ORG-0003Official name: Sykehusinnkjøp HF, divisjon legemidler\n Registration number: 916879067\n Postal address: Grev Wedels Plass 7 5. etasje \n \n \n Country subdivision (NUTS): Oslo (NO081)\n \n Contact point: Eirik Sverrisson\n Email: legemidler@sykehusinnkjop.no\n \n Internet address: http://www.sykehusinnkjop.no\n Roles of this organisation:\n \n \n 8.1 ORG-0004Official name: Klagenævnet for Udbud\n Registration number: 37795526\n Postal address: Nævnenes Hus Toldboden 2 \n \n \n Country subdivision (NUTS): Østjylland (DK042)\n \n Email: klfu@naevneneshus.dk\n \n Internet address: https://klfu.naevneneshus.dk\n Roles of this organisation:\n \n \n 8.1 ORG-0005Official name: Konkurrence- og Forbrugerstyrelsen\n Registration number: 10294819\n Postal address: Carl Jacobsens vej 35 \n \n \n Country subdivision (NUTS): Byen København (DK011)\n \n \n \n Internet address: http://www.kfst.dk\n Roles of this organisation:Organisation providing more information on the review procedures\n \n \n 8.1 ORG-0006Official name: B. Braun Medical A/S\n Registration number: 20343249\n Postal address: Dirch Passers Alle 27, 3 sal \n \n \n Country subdivision (NUTS): Byen København (DK011)\n \n Email: kundeservice-dk@bbraun.com\n \n Internet address: https://bbraun.dk\n Roles of this organisation:\n \n \n 8.1 ORG-0007Official name: B. Braun Medical AS\n Size of the economic operator: Micro, small, or medium\n Registration number: 914 113 172\n Postal address: Mathilde Henriksens vei 1 \n \n \n Country subdivision (NUTS): Østfold (NO083)\n \n Email: kundeservice.no@bbraun.com\n Telephone: +47 33 35 18 00\n Internet address: https://www.bbraun.no\n Roles of this organisation:\n Winner of these lots: LOT-0006, LOT-0013\n \n \n 8.1 ORG-0008Official name: Fresenius Kabi\n Size of the economic operator: Micro, small, or medium\n Registration number: 21347809\n Postal address: Islands Brygge 57 \n \n \n Country subdivision (NUTS): Byen København (DK011)\n \n Email: info-dk@fresenius-kabi.com\n \n Internet address: https://www.fresenius-kabi.dk\n Roles of this organisation:\n Winner of these lots: LOT-0001, LOT-0005, LOT-0007\n \n \n 8.1 ORG-0009Official name: Accord Healthcare A/S\n Size of the economic operator: Micro, small, or medium\n Registration number: 556810-0258\n Postal address: Frösundaviks Allé 1 \n \n \n Country subdivision (NUTS): Stockholms län (SE110)\n \n Email: info_sweden@accord-healthcare.com\n \n Internet address: https://www.accord-healthcare.com/se/\n Roles of this organisation:\n Winner of these lots: LOT-0009, LOT-0010\n \n \n 8.1 ORG-0010Official name: Hameln Pharma ApS\n Size of the economic operator: Micro, small, or medium\n Registration number: 39720213\n Postal address: Naverland 22 \n \n \n Country subdivision (NUTS): Københavns omegn (DK012)\n \n Email: rp@hameln-pharma.dk\n \n Internet address: https://www.hameln-pharma.com\n Roles of this organisation:\n Winner of these lots: LOT-0002\n \n \n 8.1 ORG-0011Official name: Pfizer ApS\n Size of the economic operator: Micro, small, or medium\n Registration number: 66351912\n Postal address: Lautrupvang 8 \n \n \n Country subdivision (NUTS): Københavns omegn (DK012)\n \n Email: Medical.Information@pfizer.com\n \n Internet address: https://www.pfizer.dk\n Roles of this organisation:\n Winner of these lots: LOT-0003, LOT-0004\n \n \n 8.1 ORG-0012Official name: Sandoz A/S\n Size of the economic operator: Micro, small, or medium\n Registration number: 27744532\n Postal address: Edvard Thomsens Vej 14 \n \n \n Country subdivision (NUTS): Byen København (DK011)\n \n Email: info.sandoz-dk@sandoz.com\n \n Internet address: https://www.sandoz.dk\n Roles of this organisation:\n Winner of these lots: LOT-0011, LOT-0012\n \n \n 8.1 ORG-0013Official name: Baxter A/S\n Size of the economic operator: Micro, small, or medium\n Registration number: 72246012\n Postal address: Tobaksvejen 23A \n \n \n Country subdivision (NUTS): Københavns omegn (DK012)\n \n Email: kundeservice_danmark@baxter.com\n \n Internet address: http://www.baxter.dk\n Roles of this organisation:\n Winner of these lots: LOT-0014\n \n \n 8.1 ORG-0000Official name: Publications Office of the European Union\n Registration number: PUBL\n \n \n Country subdivision (NUTS): Luxembourg (LU000)\n \n Email: ted@publications.europa.eu\n \n Internet address: https://op.europa.eu\n Roles of this organisation:\n \n \n \n Notice informationNotice identifier/version: 2ea07466-95f9-4486-904b-0b62a147be59 - 01\n \n Notice type: Contract or concession award notice – standard regime\n Notice dispatch date: 10-06-2025 09:29 +00:00\n Languages in which this notice is officially available: English \n Notice publication number: 00373008-2025\n OJ S issue number: 110/2025\n Publication date: 11-06-2025\n \n \n","opsummeringDA":{"card":{"titel":"Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a","ordregiver":"Amgros I/S","ordregiverId":"14479880","ordregiverIdDatavasket":"14479880","publiceringsdato":"2025-06-11+02:00","cpvKode":"33600000","cpvTitel":"Lægemidler","formulartype":"Resultater","formulartypeKode":"result","tidsfrister":[],"alleOrdregivere":["Amgros I/S","Landspítali Háskólasjúkrahús","Sykehusinnkjøp HF, divisjon legemidler"],"anslaaetVaerdi":"18146993","anslaaetVaerdiValuta":"EUR","beskrivelse":"Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group, the pharmaceuticals are tendered under each lot no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see the tender specification. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.","bkSubTypeKode":"29","bkSubType":"Bekendtgørelse om indgåede kontrakter – det generelle direktiv, standardordningen","erAendring":false},"indholdsType":"HENTET_FRA_TED","sekundaereOrdregivere":["Landspítali Háskólasjúkrahús","Sykehusinnkjøp HF, divisjon legemidler"],"udforelsesstedNutsCode":["DK011"],"udforelsesstedSubLand":["Byen København"],"udforelsesstedLand":["Danmark"],"udforelsesstedBy":[],"tilbudsfrister":[],"intressentfrister":[],"deltagelsefrister":[],"svarfrister":[],"antalParts":0,"antalLots":14,"udbudsDokumenter":[]},"opsummeringEN":{"card":{"titel":"Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a","ordregiver":"Amgros I/S","ordregiverId":"14479880","ordregiverIdDatavasket":"14479880","publiceringsdato":"2025-06-11+02:00","cpvKode":"33600000","cpvTitel":"Pharmaceutical products","formulartype":"Result","formulartypeKode":"result","tidsfrister":[],"alleOrdregivere":["Amgros I/S","Landspítali Háskólasjúkrahús","Sykehusinnkjøp HF, divisjon legemidler"],"anslaaetVaerdi":"18146993","anslaaetVaerdiValuta":"EUR","beskrivelse":"Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group, the pharmaceuticals are tendered under each lot no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see the tender specification. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.","bkSubTypeKode":"29","bkSubType":"Contract award notice – general directive, standard regime","erAendring":false},"indholdsType":"HENTET_FRA_TED","sekundaereOrdregivere":["Landspítali Háskólasjúkrahús","Sykehusinnkjøp HF, divisjon legemidler"],"udforelsesstedNutsCode":["DK011"],"udforelsesstedSubLand":["Byen København"],"udforelsesstedLand":["Denmark"],"udforelsesstedBy":[],"tilbudsfrister":[],"intressentfrister":[],"deltagelsefrister":[],"svarfrister":[],"antalParts":0,"antalLots":14,"udbudsDokumenter":[]}}